Saturday, November 21, 2026Canada's Indigenous Health, Employment & Community News · RSS
I Health TodayIndigenous health, employment and community news in Canada

Health Canada Approves New Eli Lilly GLP-1 Pill for Weight Loss

Health Canada has authorized Eli Lilly's Foundayo, a daily GLP-1 pill for weight loss and Type 2 diabetes management, offering an alternative to injectable treatments.

· Global News Health

CANADA — Health Canada has approved Eli Lilly’s Foundayo, a new GLP-1 medication for weight loss and Type 2 diabetes management. Unlike existing injectable treatments, Foundayo is a daily oral pill, offering a more convenient option for patients struggling with obesity or overweight conditions accompanied by related health issues such as high blood pressure or sleep apnea.

Foundayo contains orforglipron, a non-peptide GLP-1 receptor agonist. Its smaller molecular structure allows it to be absorbed orally without being broken down by the digestive system, a significant advancement in GLP-1 treatments. Dr. Ehud Ur, a Vancouver-based endocrinologist, noted that orforglipron appears to be as effective, if not more so, than existing injectable GLP-1 medications like semaglutide and tirzepatide.

The approval of Foundayo introduces a new option in a competitive market dominated by injectable drugs such as Eli Lilly’s Mounjaro and Zepbound, and Novo Nordisk’s Ozempic and Wegovy. While Novo Nordisk’s Rybelsus is another GLP-1 pill available in Canada, it is only approved for Type 2 diabetes management, not weight loss.

Common side effects of GLP-1 medications, including Foundayo, include gastrointestinal issues such as nausea and vomiting. Dr. Ur emphasized that prescribing Foundayo will depend on individual patient needs, particularly as clinical trial data on its cardiovascular benefits are still pending.

Eli Lilly expects Foundayo to be available in Canadian pharmacies by January 2027. Meanwhile, Novo Nordisk is awaiting Health Canada approval for its Wegovy pill, which would provide another oral GLP-1 option for weight loss. Both medications are already approved and available in the United States.

The introduction of oral GLP-1 medications marks a significant shift in weight-loss treatment, offering patients alternatives to injectable therapies. As more options become available, healthcare providers will have greater flexibility in tailoring treatments to individual needs. Reported with files from Global News Health.

Mainstream News

Bed Bug Infestation Forces Closure of Fort Simpson Schools

· CBC North

Two schools in Fort Simpson, N.W.T., will close starting Monday due to a bed bug infestation, with no confirmed reopening date.

Mainstream News

The Complex History of Bible Translations in Greenland and Labrador

· Nunatsiaq News

Early Christian missionaries in Greenland and Labrador relied on Inuit converts to translate the Bible, revealing a complex interplay of cultural exchange and religious adaptation.

Mainstream News

Inuit-Led Pirutsiagutiit Program Replaces Child First Initiative

· Nunatsiaq News

Federal government transfers $575M in child health and social support funding to Inuit organizations, ending uncertainty over previous program.

Mainstream News

Whitehorse Students Engage With Canadian Astronauts Aboard the ISS

· CBC North

Students from Whitehorse schools connected with Canadian astronauts Jenni Gibbons and Joshua Kutryk, gaining insights into space exploration and inspiring future careers in science.